---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-24-000004"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:22:48.542283+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Moderna reports preliminary 2023 product sales ~$6.7B; guides 2024 sales ~$4B, targets break-even 2026

## Summary
- 2023 COVID-19 vaccine product sales ~$6.7B (incl. $0.6B deferred revenue from GAVI).
- Cash, cash equivalents & investments >$13B at Dec 31, 2023.
- 2024 product sales guidance ~$4B, mostly H2; targets break-even by 2026.
- RSV vaccine regulatory filings submitted; expects approvals beginning H1 2024.
- U.S. COVID-19 market share season-to-date 48% (up from 37% in 2022).

## SEC filing metadata
- accession: 0001682852-24-000004
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000004/0001682852-24-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000004/mrna-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-24-000004
- JSON: https://secwatch.observer/filing/0001682852-24-000004.json
- Plain text: https://secwatch.observer/filing/0001682852-24-000004.txt

## Key facts
- Earnings Releases
  Moderna, Inc. reported fiscal year ended December 31, 2023 results: revenue approximately $6.7 billion in product sales.
  - Period: fiscal year ended December 31, 2023
  - Revenue: approximately $6.7 billion in product sales
  - Result: preliminary results
  source text: On January 8, 2024 , Moderna, Inc. (the “Company”) issued a press release (the “Press Release”) in connection with the Company’s presentation on the same date at the 42nd Annual J.P. Morgan Healthcare Conference. The Press Release contains certain preliminary financial information as of and for the fiscal year ended December 31, 2023. Specifically, the Press Release states that (i) the Company generated approximately $6.7 billion in product sales (unaudited) for the fiscal year ended December 31, 2023 from sales of its COVID-19 vaccine, including recognition of approximately $0.6 billion of deferred revenue related to the Company’s efforts with GAVI, The Vaccine Alliance, and (ii) the Company’s current expectation with respect to its cash, cash equivalents and investments in marketable securities (unaudited) as of December 31, 2023 were in excess of $13 billion.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000004/0001682852-24-000004-index.htm
- Earnings Releases
  Moderna, Inc. reported fiscal year ended December 31, 2023 results: revenue approximately $6.7 billion in product sales.
  - Period: fiscal year ended December 31, 2023
  - Revenue: approximately $6.7 billion in product sales
  - Result: preliminary results
  source text: Moderna achieved 2023 COVID-19 vaccine sales of approximately $6.7 billion (unaudited). This includes approximately $6.1 billion of COVID-19 vaccine sales, and recognition of approximately $0.6 billion of deferred revenue related to the Company’s efforts with GAVI, The Vaccine Alliance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000004/0001682852-24-000004-index.htm
- Earnings Releases
  Moderna, Inc. reported 2024 results: revenue approximately $4 billion in product sales in 2024. Guidance reaffirmed.
  - Period: 2024
  - Revenue: approximately $4 billion in product sales in 2024
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Company reiterates 2024 expected product sales of approximately $4 billion, planned return to sales growth in 2025 and expectation to break even in 2026 through product launches and disciplined investment
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000004/0001682852-24-000004-index.htm
- Earnings Releases
  Moderna, Inc. reported 2024 results: revenue approximately $4 billion in product sales in 2024. Guidance reaffirmed.
  - Period: 2024
  - Revenue: approximately $4 billion in product sales in 2024
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Moderna continues to project approximately $4 billion in product sales in 2024, mostly in the second half of the year, primarily due to COVID-19 vaccine sales and the launch of its RSV vaccine.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000004/0001682852-24-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.